Evaluation of Autologous Hematopoietic Stem Cell Transplantation Results of the Patients with Hodgkin Lymphoma: A Single Center Experience


Turgut T., GÜNDÜZ E., Akay O. M., ÜSKÜDAR TEKE H., Bolluk O., Gulbas Z.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.25, no.1, pp.38-43, 2015 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 1
  • Publication Date: 2015
  • Doi Number: 10.4999/uhod.15631
  • Journal Name: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.38-43
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

In this study data of 45 patients with Hodgkin lymphoma who underwent autologous hematopoietic stem cell transplantation between July 2000 and January 2012 were evaluated retrospectively. Clinical, laboratory and demographic characteristics affecting disease free survival (DFS) and overall survival (OS) were evaluated. Relapse and mortality rates in second and fifth years were also calculated. According to our results, patients in remission status before transplantation had a longer OS (p = 0.031) and relapse after transplantation shortened OS (p = 0.016). High beta 2 microglobulin level was associated with a shorter disease free survival (p = 0.042). Four patients (8.8%) died and 14 patients (31.1%) relapsed in the second year; 7 patients (%15.5) died and 17 patients (37.7%) relapsed in the fifth year. Median survival was 39 (6-72) months. In conclusion, autologous hematopoietic stem cell transplantation can be a salvage treatment for selected Hodgkin lymphoms patients who relapsed but it is important to evaluate prognostic factors and long term outcomes in terms of relapse and mortality after transplantation. Sharing experience from different transplantation centers can help selecting the most suitable patient for autologous transplantation.